首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Cancer Letters

Cancer Letters杂志,由Elsevier Ireland Ltd出版,于1975年创刊,Biweekly,出版语言English,ISSN:0304-3835,E-ISSN:1872-7980。

投稿咨询
Cancer Letters
Cancer Letters
Cancer Letters
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
11.8
CiteScore
15.4
期刊收录
SCI、SCIE

Cancer Letters(中文译名:《癌症快报》),ISSN:0304-3835,EISSN:1872-7980,是Elsevier Ireland Ltd出版的国际性学术期刊,创刊于1975年,以Biweekly形式稳定发行,2026年总发文量约493篇。该刊采用非OA开放访问,学科归属为医学 - 肿瘤学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达11.8,2025年期刊CiteScore为15.4,2025年期刊自引率约9.3%,在中科院期刊分区体系中位列医学大类1区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Cancer Letters长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期约2.7个月,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,CHINA MAINLANDUSA、South Korea、GERMANY (FED REP GER)、Italy、Japan、Taiwan等为核心发文国家与地区;CHINESE ACADEMY OF SCIENCESSHANGHAI JIAO TONG UNIVERSITY、SUN YAT SEN UNIVERSITY、CHINESE ACADEMY OF MEDICAL SCIENCES - PEKING UNION MEDICAL COLLEGE、FUDAN UNIVERSITY、NANJING MEDICAL UNIVERSITY、ZHEJIANG UNIVERSITY等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
1区
是 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
2区
是 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
2区
是 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 29 / 333

91.4

学科:ONCOLOGY SCIE Q1 24 / 333

92.94

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 30 / 328

91

学科:ONCOLOGY SCIE Q1 25 / 328

92.53


中国学者近期发文

1
RNF185 orchestrates replication fork restart and homologous recombination through temporal RPA1 ubiquitination switchin

Author:Yao, Zhicheng; Wang, Ruru; Chen, Bin; Zhao, Xipeng; Zhang, Jie; Zhou, Shenglan; Xu, An; Wu, Lijun; Zhang., Jie; Xu, Feng; Zhao, Guoping

Journal: CANCER LETTERS. 2026; Vol. 650, Issue , pp. -. DOI: 10.1016/j.canlet.2026.218513

2
CD276 promotes CD36-mediated lipid metabolism and confers resistance to tyrosine kinase inhibitor

Author:Huang, Xiaojuan; Ma, Leina; Lu, Yangyang; Cui, Jinfeng; Qi, Weiwei; Song, Jialin; Guo, Jing; Wang, Shasha; Fang, Jing; Lu, Zhimin; Qiu, Wensheng

Journal: CANCER LETTERS. 2026; Vol. 650, Issue , pp. -. DOI: 10.1016/j.canlet.2026.218492

3
Integration of longitudinal MRI and biopsy whole slide images for early prediction of neoadjuvant therapy response and personalized management in breast cancer: A multicenter retrospective and prospective stud

Author:Zhang, Song; Shi, Zhihui; Du, Siyao; Zhu, Teng; Li, Pinxiong; Zhao, Ruimeng; Zhu, Xiaobo; Wu, Shiwei; Tan, Yuyi; Xu, Wenzhuo; Li, Bao; Li, Zhenhui; Wang, Kun; Zhang, Lina; Tian, Jie; Liu, Zhenyu

Journal: CANCER LETTERS. 2026; Vol. 650, Issue , pp. -. DOI: 10.1016/j.canlet.2026.218508

4
SLC28A1 inhibits clear cell renal cell carcinoma progression by affecting arachidonic acid metabolism: A novel nucleoside transporter-based targeted therapy strateg

Author:Li, Junwu; Hu, Hao; Xu, Haoyu; Zhu, Yongtang; Chen, Wenjun; Zhao, Guozhi; Patel, Harsh; Chang, Hai; Bai, Yuanyuan; Tang, Ziwei; Zhang, Yao; Tang, Wei

Journal: CANCER LETTERS. 2026; Vol. 649, Issue , pp. -. DOI: 10.1016/j.canlet.2026.218481

5
YTHDF3 facilitates DNA damage response by recognizing METTL3-mediated m6A modification to promote chemotherapy resistance in glioblastom

Author:Cheng, Meng; Pang, Ying; Wang, Rui; Chen, Xu; Zhang, Chunyu; Yang, Yuntong; Ji, Tongjie; Wu, Yueyao; Wang, Jingzhe; Xu, Siyi; Wang, Zhigang; Liu, Min; Zhang, Jing; Zhong, Chunlong

Journal: CANCER LETTERS. 2026; Vol. 649, Issue , pp. -. DOI: 10.1016/j.canlet.2026.218445

6
The therapeutic landscape and underlying mechanisms of taurine in colorectal cance

Author:Zheng, Yanyan; Liu, Huajie; Liu, Xianzhi; He, Weiling

Journal: CANCER LETTERS. 2026; Vol. 649, Issue , pp. -. DOI: 10.1016/j.canlet.2026.218480

7
MAVS in Cancer Therapy: The New STING

Author:Li, Siying; Bai, Junqiang; Wang, Xinmiao; Guo, Shutian; Guo, Xiaomeng; Shang, Zhengjun; Shao, Zhe

Journal: CANCER LETTERS. 2026; Vol. 649, Issue , pp. -. DOI: 10.1016/j.canlet.2026.218494

8
Cross-species single-cell and spatial transcriptomic mapping reveals EFNA1-EPHA4-mediated stem-like epithelial-macrophage crosstalk driving colorectal cancer progressio

Author:Zhang, Siwen; Xu, Kun; Du, Yanyun; Liu, Zhenhao; Li, Hong; Li, Bing; Xie, Lu; Zhong, Yunshi

Journal: CANCER LETTERS. 2026; Vol. 649, Issue , pp. -. DOI: 10.1016/j.canlet.2026.218495

9
Targeting the NSUN5-circPPAP2A axis reverses immunosuppression and sensitizes renal cell carcinoma to anti-PD-1 therap

Author:Gui, Chengpeng; Liu, Jinwen; Chen, Jinwei; Zhou, Xinwei; Feng, Haoqian; Fu, Liangmin; Chen, Yuhang; Zhang, Lizhen; Huang, Helang; Xu, Xin; Shu, Guannan; Zhang, Chi; Tang, Yiming; Zhu, Jiangquan; Wang, Yinghan; Wei, Jinhuan; Guo, Jianping; Zeng, Guohua; Li, Jiaying; Luo, Junhang

Journal: CANCER LETTERS. 2026; Vol. 649, Issue , pp. -. DOI: 10.1016/j.canlet.2026.218466

10
Coordinated post-transcriptional regulation facilitates PD-L1 protein production and tumor immune suppressio

Author:Chen, Ronghao; Rajasekaran, Swetha; Xing, Xuanxuan; Zhang, Qian; Steele, Sydney M.; Wang, Runjie; Babuharisankar, Ananth Ponneri; Lee, Jee Whu; Storts, Hayden; Fernandez, Francisco; Guerra-Solano, Miguel; Kumar, Vikas; Keane, Sarah C.; Walker, James A.; Wang, Jing J.; Miles, Wayne O

Journal: CANCER LETTERS. 2026; Vol. 649, Issue , pp. -. DOI: 10.1016/j.canlet.2026.218470


在线咨询

Cancer Letters

国际简称:CANCER LETT参考译名:癌症快报

年发文量:493 CiteScore:15.4 是否预警:否 Gold OA文章占比:27.90% 研究类文章占比:82.96%

杂志社联系方式:ELSEVIER IRELAND LTD, ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, IRELAND, 00000

Cancer Letters